Olivia Monteiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Olivia Monteiro has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Tomas Baptista‐Hon
Faculty of Medicine Macau University of Science and Technology Macau SAR China
9 shared publications Shuvam Sarkar
School of Medicine University of Dundee Dundee UK
3 shared publications- Ting Li
State Key Laboratory of Mechanism and Quality of Chinese Medicine/Macau Institute for Applied Research in Medicine and Health, School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, China
3 shared publications - Anand Bhaskar
Department of Physiology, Christian Medical College, Vellore, Tamil Nadu, India
2 shared publications Anna K. M. Ng
Department of Biomedical Sciences, Faculty of Medicine, Macau University of Science and Technology, Macau S.A.R., People’s Republic of China
2 shared publications- Gen Li
National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China
2 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Wiley in MedComm – Future Medicine
- Vol. 5 (4)
Looking at the Acetaminophen‐Autism Debate Through Matched Sibling Cohorts
- 14 November 2026
- Published by Wiley in MedComm – Future Medicine
- Vol. 5 (4)
Open AccessLooking at the Acetaminophen‐Autism Debate Through Matched Sibling Cohorts
- Open Access
- 1 October 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 420
Targeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis
Th17 cells are central drivers of autoimmune pathology, including multiple sclerosis (MS), yet the endogenous metabolic signals that shape their pathogenic differentiation remain incompletely defined. Prostaglandin D₂ (PGD 2 ) is traditionally viewed as an extracellular mediator in allergic diseases. Here, we identify PGD 2 as a cell-intrinsic antagonist of the nuclear receptor PPAR γ , thereby promoting Th17 cell differentiation and exacerbating EAE pathology. PGD 2 is selectively elevated in patients with MS compared with healthy individuals. Within the MS cohort, PGD 2 correlates with Th17 cell frequency and disease severity. Consistent with this association, administration of PGD 2 increases the severity of experimental autoimmune encephalomyelitis (EAE) in mice. CD4 + T cell-specific deletion of Hpgds , the key synthase for PGD 2 , impairs Th17 cell polarization and protects against EAE, whereas exogenous PGD 2 restores both Th17 cell responses and disease susceptibility. Importantly, pharmacological inhibition of HPGDS alleviates EAE symptoms in mice. Consistently, HPGDS inhibition suppresses Th17 cell differentiation in both murine and human CD4 + T cells, highlighting its translational potential. Mechanistically, PGD 2 binds directly to histidine 266 and serine 342 within the PPAR γ ligand-binding domain and suppresses its transcriptional activity, as demonstrated by site-directed mutagenesis and structure-function rescue assays in Pparg -/- T cells. Collectively, our findings define a crucial role for the HPGDS-PGD 2 axis in Th17 cell-mediated autoimmunity, establishing HPGDS as a promising therapeutic target for Th17 cell-mediated autoimmune diseases such as MS.
- 1 October 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 420
Open AccessTargeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis
Th17 cells are central drivers of autoimmune pathology, including multiple sclerosis (MS), yet the endogenous metabolic signals that shape their pathogenic differentiation remain incompletely defined. Prostaglandin D₂ (PGD 2 ) is traditionally viewed as an extracellular mediator in allergic diseases. Here, we identify PGD 2 as a cell-intrinsic antagonist of the nuclear receptor PPAR γ , thereby promoting Th17 cell differentiation and exacerbating EAE pathology. PGD 2 is selectively elevated in patients with MS compared with healthy individuals. Within the MS cohort, PGD 2 correlates with Th17 cell frequency and disease severity. Consistent with this association, administration of PGD 2 increases the severity of experimental autoimmune encephalomyelitis (EAE) in mice. CD4 + T cell-specific deletion of Hpgds , the key synthase for PGD 2 , impairs Th17 cell polarization and protects against EAE, whereas exogenous PGD 2 restores both Th17 cell responses and disease susceptibility. Importantly, pharmacological inhibition of HPGDS alleviates EAE symptoms in mice. Consistently, HPGDS inhibition suppresses Th17 cell differentiation in both murine and human CD4 + T cells, highlighting its translational potential. Mechanistically, PGD 2 binds directly to histidine 266 and serine 342 within the PPAR γ ligand-binding domain and suppresses its transcriptional activity, as demonstrated by site-directed mutagenesis and structure-function rescue assays in Pparg -/- T cells. Collectively, our findings define a crucial role for the HPGDS-PGD 2 axis in Th17 cell-mediated autoimmunity, establishing HPGDS as a promising therapeutic target for Th17 cell-mediated autoimmune diseases such as MS.
- Open Access
Generative Artificial Intelligence and Large Language Models in Clinical Oncology
Cancer remains a major global health challenge, and the increasing availability of multimodal biomedical data has created unprecedented opportunities for precision oncology. Recent advances in generative artificial intelligence (AI), particularly large language models (LLMs), have enabled new approaches for integrating heterogeneous data sources, including electronic health records, medical imaging, pathology, genomics, and clinical text. However, current studies remain fragmented across specific tasks, cancer types, and model architectures, and a comprehensive synthesis of how generative AI can support the entire oncology continuum is still lacking. This review provides an overview of generative AI in clinical oncology, covering LLMs, generative adversarial networks, diffusion models, and multimodal foundation models. We summarize their methodological foundations and discuss applications in cancer diagnosis, prognosis prediction, treatment planning, patient management, and clinical trial optimization. Particular attention is given to multimodal data integration, synthetic data generation, clinical reasoning, and decision support, together with current challenges related to interpretability, reliability, data privacy, regulatory governance, and real‐world implementation. By consolidating recent technological advances and clinical evidence, this review highlights future priorities toward safe, trustworthy, and clinically deployable intelligent oncology systems. Emerging agent‐based architectures and human–AI collaborative workflows may further expand the clinical utility of generative AI in oncology.
Open AccessGenerative Artificial Intelligence and Large Language Models in Clinical Oncology
Cancer remains a major global health challenge, and the increasing availability of multimodal biomedical data has created unprecedented opportunities for precision oncology. Recent advances in generative artificial intelligence (AI), particularly large language models (LLMs), have enabled new approaches for integrating heterogeneous data sources, including electronic health records, medical imaging, pathology, genomics, and clinical text. However, current studies remain fragmented across specific tasks, cancer types, and model architectures, and a comprehensive synthesis of how generative AI can support the entire oncology continuum is still lacking. This review provides an overview of generative AI in clinical oncology, covering LLMs, generative adversarial networks, diffusion models, and multimodal foundation models. We summarize their methodological foundations and discuss applications in cancer diagnosis, prognosis prediction, treatment planning, patient management, and clinical trial optimization. Particular attention is given to multimodal data integration, synthetic data generation, clinical reasoning, and decision support, together with current challenges related to interpretability, reliability, data privacy, regulatory governance, and real‐world implementation. By consolidating recent technological advances and clinical evidence, this review highlights future priorities toward safe, trustworthy, and clinically deployable intelligent oncology systems. Emerging agent‐based architectures and human–AI collaborative workflows may further expand the clinical utility of generative AI in oncology.
- Open Access
- 11 April 2026
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 9 (2)
JS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study
Background: Bladder cancer is the most common urological malignancy. Bladder cancer has limited therapeutic options, especially in advanced stages. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising target for cancer therapy. However, the role of autophagy in modulating ferroptosis remains incompletely understood. Methods: We investigated the anti-tumor effects of JS-K, a nitric oxide-releasing prodrug, in bladder cancer through integrated cell, animal, and patient data studies. In vitro experiments with T24 and UM-UC-3 cells were used to explore how JS-K influences cancer cell survival and the interplay between autophagy and ferroptosis. In vivo, a BALB/c nude mouse tumor model provided a system to examine tumor response and tissue-level changes. To extend these findings to the clinical setting, we analyzed LC3B expression and its associations with ferroptosis-related genes, patient prognosis, and the tumor immune microenvironment. Results: JS-K induced mitochondrial damage, lipid peroxidation, reactive oxygen species accumulation, and intracellular iron overload in bladder cancer cells in a concentration-dependent manner. These changes were accompanied by downregulation of GPX4 and SLC7A11 and upregulation of FTH1 and TFR1, indicative of ferroptosis. Inhibition or knockdown of the autophagy marker LC3B reversed these effects, establishing the role of autophagy in mediating ferroptosis. In xenograft models, JS-K suppressed tumor growth, an effect abrogated by LC3B silencing. Integrated transcriptomic and single-cell analyses revealed a strong correlation between LC3B and ferroptosis-related genes, with CISD1 identified as a key prognostic marker. Conclusions: JS-K induces autophagy-dependent ferroptosis in bladder cancer cells and significantly suppresses tumor progression. Targeting the autophagy–ferroptosis axis offers a novel therapeutic strategy for bladder cancer treatment.
- 11 April 2026
- Published by Oxford University Press (OUP) in Precision Clinical Medicine
- Vol. 9 (2)
Open AccessJS-K induces autophagy-dependent ferroptosis in bladder cancer: a multimodal mechanistic and translational study
Background: Bladder cancer is the most common urological malignancy. Bladder cancer has limited therapeutic options, especially in advanced stages. Ferroptosis, an iron-dependent form of regulated cell death, has emerged as a promising target for cancer therapy. However, the role of autophagy in modulating ferroptosis remains incompletely understood. Methods: We investigated the anti-tumor effects of JS-K, a nitric oxide-releasing prodrug, in bladder cancer through integrated cell, animal, and patient data studies. In vitro experiments with T24 and UM-UC-3 cells were used to explore how JS-K influences cancer cell survival and the interplay between autophagy and ferroptosis. In vivo, a BALB/c nude mouse tumor model provided a system to examine tumor response and tissue-level changes. To extend these findings to the clinical setting, we analyzed LC3B expression and its associations with ferroptosis-related genes, patient prognosis, and the tumor immune microenvironment. Results: JS-K induced mitochondrial damage, lipid peroxidation, reactive oxygen species accumulation, and intracellular iron overload in bladder cancer cells in a concentration-dependent manner. These changes were accompanied by downregulation of GPX4 and SLC7A11 and upregulation of FTH1 and TFR1, indicative of ferroptosis. Inhibition or knockdown of the autophagy marker LC3B reversed these effects, establishing the role of autophagy in mediating ferroptosis. In xenograft models, JS-K suppressed tumor growth, an effect abrogated by LC3B silencing. Integrated transcriptomic and single-cell analyses revealed a strong correlation between LC3B and ferroptosis-related genes, with CISD1 identified as a key prognostic marker. Conclusions: JS-K induces autophagy-dependent ferroptosis in bladder cancer cells and significantly suppresses tumor progression. Targeting the autophagy–ferroptosis axis offers a novel therapeutic strategy for bladder cancer treatment.
- Top Cited PapersOpen Access
- 16 February 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 55
Lipid metabolism in homeostasis and disease
Lipid metabolism is essential for maintaining cellular homeostasis, and its dysregulation is linked to various diseases, including cancer, cardiovascular disease, and diabetes. Immune cells, such as macrophages, T cells, B cells, and neutrophils, rely on lipid metabolism for their function, which impacts both innate and adaptive immune responses. Understanding how lipid metabolism influences immune cells is crucial, as it can reveal new therapeutic opportunities for immune-mediated diseases. In this review, we provide a retrospective summary of the research history and milestone events in lipid metabolism research and highlight the importance of lipid metabolism in immune cells. In addition to discussing the various lipid functions, transport, and signaling pathways involved in lipid metabolism, we mainly explore the regulation of immune cell behavior by lipid metabolism, focusing on the roles of lipid metabolites in immune cell proliferation, differentiation, and activation. We further highlight multilevel regulatory mechanisms, including genetic, epigenetic, posttranscriptional, and posttranslational regulation, and their impact on immune cell function. Additionally, we discuss the role of lipid metabolism in diseases such as autoimmune diseases, cancer, neurodegenerative diseases, cardiovascular diseases, aging, and metabolic disorders. Finally, we summarize therapeutic strategies targeting lipid metabolism, the progress of global clinical trials, and future research directions, including lipid-derived biomarkers and innovative therapeutic approaches.
- 16 February 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 55
Top Cited PapersOpen AccessLipid metabolism in homeostasis and disease
Lipid metabolism is essential for maintaining cellular homeostasis, and its dysregulation is linked to various diseases, including cancer, cardiovascular disease, and diabetes. Immune cells, such as macrophages, T cells, B cells, and neutrophils, rely on lipid metabolism for their function, which impacts both innate and adaptive immune responses. Understanding how lipid metabolism influences immune cells is crucial, as it can reveal new therapeutic opportunities for immune-mediated diseases. In this review, we provide a retrospective summary of the research history and milestone events in lipid metabolism research and highlight the importance of lipid metabolism in immune cells. In addition to discussing the various lipid functions, transport, and signaling pathways involved in lipid metabolism, we mainly explore the regulation of immune cell behavior by lipid metabolism, focusing on the roles of lipid metabolites in immune cell proliferation, differentiation, and activation. We further highlight multilevel regulatory mechanisms, including genetic, epigenetic, posttranscriptional, and posttranslational regulation, and their impact on immune cell function. Additionally, we discuss the role of lipid metabolism in diseases such as autoimmune diseases, cancer, neurodegenerative diseases, cardiovascular diseases, aging, and metabolic disorders. Finally, we summarize therapeutic strategies targeting lipid metabolism, the progress of global clinical trials, and future research directions, including lipid-derived biomarkers and innovative therapeutic approaches.
- Open Access
- 2 April 2025
- Published by Wiley in MedComm – Future Medicine
- Vol. 4 (2)
Artificial Intelligence in Medical Education: A Practical Guide for Educators
Artificial intelligence (AI)‐driven learning is transforming education, requiring educators to quickly develop the skills to integrate AI tools effectively so they complement rather than replace traditional teaching practices. The fast pace of generative AI development poses challenges, particularly for less tech‐savvy teachers or those who delay learning about these tools, leaving them at risk of falling behind. This is further compounded by students' quick adaptation to widely available models such as ChatGPT‐3.5 and Deepseek R1, which they increasingly use for learning, assignments, and assessments. Despite existing discussions on AI in education, there is a lack of practical guidance on how medical educators can effectively and responsibly implement AI tools in teaching. This perspective provides a practical guide for medical educators to effectively incorporate AI tools to complement their teaching strategies, generate student assessments and to adapt assignments suitable for the AI era. We address challenges such as data bias, accuracy, and ethics, ensuring AI enhances rather than undermines medical training when aligned with sound pedagogical principles. This review provides a practical, structured approach for educators, offering clear recommendations to help bridge the gap between AI advancements and effective teaching methodologies in medical education.
- 2 April 2025
- Published by Wiley in MedComm – Future Medicine
- Vol. 4 (2)
Open AccessArtificial Intelligence in Medical Education: A Practical Guide for Educators
Artificial intelligence (AI)‐driven learning is transforming education, requiring educators to quickly develop the skills to integrate AI tools effectively so they complement rather than replace traditional teaching practices. The fast pace of generative AI development poses challenges, particularly for less tech‐savvy teachers or those who delay learning about these tools, leaving them at risk of falling behind. This is further compounded by students' quick adaptation to widely available models such as ChatGPT‐3.5 and Deepseek R1, which they increasingly use for learning, assignments, and assessments. Despite existing discussions on AI in education, there is a lack of practical guidance on how medical educators can effectively and responsibly implement AI tools in teaching. This perspective provides a practical guide for medical educators to effectively incorporate AI tools to complement their teaching strategies, generate student assessments and to adapt assignments suitable for the AI era. We address challenges such as data bias, accuracy, and ethics, ensuring AI enhances rather than undermines medical training when aligned with sound pedagogical principles. This review provides a practical, structured approach for educators, offering clear recommendations to help bridge the gap between AI advancements and effective teaching methodologies in medical education.
- Open Access
- 4 December 2024
- Published by Wiley in MedComm – Future Medicine
- Vol. 3 (4)
Long COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
Long coronavirus disease (COVID) is characterized by persistent symptoms following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and has emerged as a significant health concern. As SARS‐CoV‐2 evolved from the wild‐type strain to the Alpha, Beta, Delta, and Omicron variants, there may be a variant‐specific influence on long COVID akin to the acute disease. This review aims to summarize our current knowledge of variant‐specific influences in long COVID incidence, symptom profile as well as mechanisms of pathogenesis. We highlight that long COVID incidence may be lower with the Omicron variants. The symptom profile of long COVID may also show some dependence on the different variants, with a reduction in cardiopulmonary symptoms with more recent SARS‐CoV‐2 variants. This heterogeneity of long COVID may also be related to the variant‐specific differences in affecting the immune system, viral persistence, and autoimmunity. However, emerging data also suggest that vaccinations may play a big role in shaping the presentation of long COVID. We also highlight ongoing work on long COVID incidence and symptom profiles in populations infected only by the Omicron variants. This will be beneficial toward more useful disease definitions and the development of effective diagnostic and therapeutic strategies.
- 4 December 2024
- Published by Wiley in MedComm – Future Medicine
- Vol. 3 (4)
Open AccessLong COVID across SARS‐CoV‐2 variants: Clinical features, pathogenesis, and future directions
Long coronavirus disease (COVID) is characterized by persistent symptoms following severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and has emerged as a significant health concern. As SARS‐CoV‐2 evolved from the wild‐type strain to the Alpha, Beta, Delta, and Omicron variants, there may be a variant‐specific influence on long COVID akin to the acute disease. This review aims to summarize our current knowledge of variant‐specific influences in long COVID incidence, symptom profile as well as mechanisms of pathogenesis. We highlight that long COVID incidence may be lower with the Omicron variants. The symptom profile of long COVID may also show some dependence on the different variants, with a reduction in cardiopulmonary symptoms with more recent SARS‐CoV‐2 variants. This heterogeneity of long COVID may also be related to the variant‐specific differences in affecting the immune system, viral persistence, and autoimmunity. However, emerging data also suggest that vaccinations may play a big role in shaping the presentation of long COVID. We also highlight ongoing work on long COVID incidence and symptom profiles in populations infected only by the Omicron variants. This will be beneficial toward more useful disease definitions and the development of effective diagnostic and therapeutic strategies.
- Open Access
- 20 October 2024
- Published by Wiley in MedComm – Future Medicine
- Vol. 3 (4)
Unlocking longevity: How blocking IL‐11 signaling could extend healthspan and lifespan
- 20 October 2024
- Published by Wiley in MedComm – Future Medicine
- Vol. 3 (4)
Open AccessUnlocking longevity: How blocking IL‐11 signaling could extend healthspan and lifespan
- Open Access
- 23 April 2024
- Published by Wiley in MedComm – Future Medicine
- Vol. 3 (2)
Understanding long COVID—The role of serotonin in cognitive impairment
- 23 April 2024
- Published by Wiley in MedComm – Future Medicine
- Vol. 3 (2)
Open AccessUnderstanding long COVID—The role of serotonin in cognitive impairment